New drug formulations of colony-stimulating factors in oncohematology
https://doi.org/10.17650/1818-8346-2023-18-1-126-131
Abstract
The use of colony-stimulating factors became an autonomous approach in complex supportive care of blood tumors. By indications of granulocyte colony-stimulating factor (G-CSF) it is possible to reduce of neutropenic period, perform an optimal timing of therapy, decrease a number of infection complications. The development and active use of a new G-CSF drug formulation – pegfilgrastim do not decrease the duration of neutropenic period significantly, but reduced the frequency of drug administration, period of hospitalization and a probability of “ineffective” hematopoietic stem cell mobilization.
In the current issue it is presented the results of modern studies, which demonstrate advantages of PEG-G-CSF in contrast to G-CSF, algorithm for febrile neutropenia risk assessment, the questions for G-CSF administrations in patients with blood tumors.
About the Authors
T. T. Valiev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Timur Teymurazovich Valiev
115478, Moscow, Kashirskoe Shosse, 24
119991, Moscow, Trubetskaya St., 8, Build. 2
R. R. Fatkhullin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
115478, Moscow, Kashirskoe Shosse, 24
Yu. E. Ryabukhina
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
143081, Moscow region, Lapino, 1st Uspenskoe Shosse, 111
P. A. Zeynalova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
119991, Moscow, Trubetskaya St., 8, Build. 2
143081, Moscow region, Lapino, 1st Uspenskoe Shosse, 111
References
1. Caetano Dos Santos F.L., Michalek I.M., Wojciechowska U. et al. Improved survival of Burkitt lymphoma/leukemia patients: observations from Poland, 1999–2020. Ann Hematol 2022;101(5):1059–65. DOI:10.1007/s00277-022-04758-2
2. Baryakh E.A., Kremenetskaya A.M., Kravchenko S.K. et al. A new short intensive protocol BL-M-04 for therapy of Burkitt lymphoma in adults: intermediate results. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2006;51(6):3–11. (In Russ.).
3. Valiev T.T., Morozova O.V., Popa A.V., Mentkevich G.L. Treatment outcomes for Burkitt’s lymphoma in children. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2012;57(S3):34. (In Russ.).
4. Akhmerzaeva Z.Kh., Parovichnikova E.N., Troitskaya V.V. et al. 10-year milestone: long-term survival rates in patients with acute Ph-negative lymphoblastic leukemia according to the ALL-2009 protocol (results of the Russian research group on acute lymphoblastic leukemia study). Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2020;65(Suppl. 1):58. (In Russ.).
5. Aleskerova G.A., Shervashidze M.A., Popa A.V. et al. Treatment results of acute lymphoblastic leukemia in children according to the ALL IC-BFM 2002 protocol. Onkopediatriya = Oncopediatrics 2016;3(4):302–8. (In Russ.). DOI:10.15690/onco.v3i4.1635
6. Engert A., Bredenfeld H., Döhner H. et al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: results of a phase II study. Haematologica 2006;91(4):546–9.
7. Snegovoy A.V., Kagoniya L.M., Kononenko I.B. et al. Practical recommendations for colony-stimulating factors administration to prevent febrile neutropenia development in cancer patients. Zlokachestvennye opukholi = Malignant tumors 2015;(4, special issue):342–9. (In Russ.). DOI:10.18027/2224-5057-2015-4s-342349
8. Bariakh E.A., Tiurina N.G., Vorob’ev V.I. et al. Therapy for Burkitt’s lymphoma according to the BL-M-04 protocol: 12-year experience. Terapevticheskii arkhiv = Therapeutic Archive 2015;87(7):4–14. (In Russ.). DOI:10.17116/terarkh20158774-14
9. Valiev T.T., Shervashidze M.A., Osipova I.V. et al. Protocol ALL-IC BFM 2002: outcomes of pediatric acute lymphoblastic leukemia treatment under multi-center clinical trial. Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Basic Research and Clinical Practice 2022;15(2):119–29. (In Russ.). DOI:10.21320/2500-21392022-15-2-119-129
10. Lee Y.M., Lockwood C. Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis. Int J Nurs Pract 2013;19(6):557–76. DOI:10.1111/ijn.12099
11. Gurieva O.D., Savelyeva M.I., Valiev T.T. Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review). Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2021;8(4):60–70. (In Russ.). DOI:10.21682/2311-1267-2021-8-4-60-70
12. Tsukamoto T., Sogo T., Ueyama T. et al. Chimeric G-CSF receptormediated STAT3 activation contributes to efficient induction of cardiomyocytes from mouse induced pluripotent stem cells. Biotechnol J 2020;15(2):e1900052. DOI:10.1002/biot.201900052
13. Babicheva L.G., Podvyaznikov S.O. Prevention of neutropenia as an important factor in successful chemotherapy for head and neck cancer. Opukholi golovy i shei = Head and Neck Tumors 2021;11(3): 72–82. (In Russ.). DOI:10.17650/2222146820211137282
14. Koumakis G., Vassilomanolakis M., Barbounis V. et al. Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology 1999;56(1):28–35. DOI:10.1159/000011926
15. Molineux G., Kinstler O., Briddell B. et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27(12):1724–34. DOI:10.1016/s0301-472x(99)00112-5
16. Fishburn C.S. The pharmacology of PEGylation: balancing PG with PK to generate novel therapeutics. J Pharm Sci 2008;97(10):4167–83. DOI:10.1002/jps.21278
17. Pasut G., Veronese F.M. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release 2012;161(2):461–72. DOI:10.1016/j.jconrel.2011.10.037
18. Green M.D., Koelbl H., Baselga J. et al. A randomized doubleblind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14(1):29–35. DOI:10.1093/annonc/mdg019
19. Kubo K., Miyazaki Y., Murayama T. et al. A randomized, doubleblind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. Br J Haematol 2016;174(4):563–70. DOI:10.1111/bjh.14088
20. Rudakova A.V., Tolkacheva D.G., Gavrilova O.N., Vaganov A.S. Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast. Sovremennaya onkologiya = Journal of Modern Oncology 2016;18(2):48–51. (In Russ.).
Review
For citations:
Valiev T.T., Fatkhullin R.R., Ryabukhina Yu.E., Zeynalova P.A. New drug formulations of colony-stimulating factors in oncohematology. Oncohematology. 2023;18(1):126-131. (In Russ.) https://doi.org/10.17650/1818-8346-2023-18-1-126-131
Views:
8636
Email this article 